Home Controlled Substances As Coronavirus Cases Spike, Washington Marijuana Dispensaries Permitted to Remain Open

As Coronavirus Cases Spike, Washington Marijuana Dispensaries Permitted to Remain Open

-

Washington Marijuana Dispensaries Permitted to Remain Open

As the cases of coronavirus continue to climb in the United States of America, the cannabis dispensaries in Washington have been permitted to remain operational. However, the state Governor Jay Inslee on Monday has ordered the closure of non-essential businesses. Jay Inslee has issued the directive of staying at home to check the further spread of deadly novel coronavirus (COVID-19). According to a report, the total number of cases in the USA has now mounted to 68,489; with 1032 people have already died due to the virus so far. 278 cases have already been reported, and five people have died due to the virus today only.

Jay Inslee’s order has become effective for citizens right from Monday afternoon and will become effective for business organizations on Wednesday. The Governor’s order “Stay Home, Stay Healthy” is scheduled to continue for two weeks. As per the order, all the businesses considered to be non-essential will stop operations that may not be completed by workers from home. Washington citizens have been asked to pay heed to state public health advisories of staying home as reports are surfacing that now America may emerge as the new epicenter of the highly contagious pandemic. Residents in Washington can step out of their homes only to purse important activities.

Meanwhile, the Washington State Liquor and Cannabis Board or WSLCB has permitted dispensaries to permit customers to collect their orders outside the business at curbside. Earlier, the practice was followed only for medical cannabis patients.

 

FBI reviewing CBD use policy for agents

The Federal Bureau of Investigation said its policy on CBD use by agents is currently “under review.”

Marijuana Moment took a look at how Charlotte Figi—the 13-year-old CBD pioneer who passed away this week from a likely coronavirus infection—inspired state lawmakers to enact new Cannabidiol-focused laws which in turn essentially forced Congress to pass a budget rider protecting all state medical cannabis programs from federal interference. Meanwhile, messages of condolence for her family are pouring in from state and federal senators and representatives from across the country.

A coalition of marijuana industry groups is asking states for access to coronavirus-related loans and assistance that the federal government won’t provide. “Like all essential businesses, cannabis businesses are facing significant uncertainty and costs to provide for our employees and to maintain the medical supply chain during this pandemic. Yet, unlike every other essential business, there is an underlying federal-state tension that puts our businesses in a uniquely vulnerable and dire operational and financial position. This is particularly true of our small and minority-owned businesses.”

 

The study suggests the frequency and severity of negative reactions to cannabis

The study notes that in the United States, medicinal cannabis use is now legal in 33 states, as well as the District of Columbia (D.C.). Meanwhile, 11 states, D.C., and Canada have legalized recreational cannabis use. Consequently, more people who have not used cannabis before may try the drug in the future. As the authors note, these users “may have limited knowledge of the possible adverse effects of cannabis.” The authors, therefore, wanted to find out more about what types of adverse reactions happen when someone uses cannabis, how likely they are to occur, and what factors might make a person more likely to experience them.

The team was specifically interested in acute adverse reactions, in which negative side effects happen for a short duration. The authors note that previous research has explored different chronic adverse reactions to cannabis use, whereas there is less research on acute adverse effects. Dr. Carrie Cuttler, an assistant professor of psychology at Washington State University, Pullman, and one of the paper’s authors, notes, “There have been surprisingly little research on the prevalence or frequency of various adverse reactions to cannabis and almost no research trying to predict who is more likely to experience these types of adverse reactions.”

“With the legalization of cannabis in Washington and 10 other states, we thought it would be important to document some of this information so that more novice users would have a better sense of what types of adverse reactions they may experience if they use cannabis.”

 

What to know about vaping CBD

With its legalization in many countries around the world, many people have started to use Cannabidiol (CBD) products for its potential medical benefits. CBD users ingest the compound in various ways, including vaping.

Some studies suggest that CBD may help treat some chronic conditions, such as anxiety and pain. However, most studies have evaluated the effects of taking CBD orally and not through inhalation. The Centers for Disease Control and Prevention (CDC) recommend against vaping, as the long-term effects are still unknown. Studies on vaping CBD oil are lacking. Most clinical trials around CBD have focused on oral capsules, sublingual sprays, or oral solutions.

People living with asthma and chronic obstructive pulmonary disease often use aerosolized therapies. This delivery system supplies the medication directly into the lungs, which results in a rapid clinical effect. Generally, people also need smaller doses compared with oral or subcutaneous injections. The features of condensation aerosols can make vaping seem like a more effective method of taking CBD. However, since vaping is still a relatively new practice, researchers are unclear about its benefits and risks and need to conduct further investigations.

 

COVID-19 Could Add Impetus to Campaigns for Marijuana Home Cultivation

Patients and industry players alike have applauded the decision by numerous states to classify marijuana as an essential commodity, allowing medical and recreational marijuana stores to remain open. As the Coronavirus pandemic ravages the U.S., several state governments have implemented statewide lockdowns to curb its spread.

People are to practice self-isolation and only head outside for essentials like food and medicine, and all but the most essential businesses have been ordered to close. They are also encouraged to wash their hands with soap and water or hand sanitizer regularly.

The open businesses include supermarkets, pharmacies, and daycare centers, and they have permission to operate during the lockdown as they provide essential goods and services. Fortunately for the many people who rely on marijuana to deal with a variety of health issues, numerous states have stated that marijuana is just as essential. They have taken additional steps such as allowing curbside pickups and home deliveries to ensure both the sellers and patients stay safe as they transact. According to some, allowing people to grow their marijuana at home might make the self-isolation and social distancing measures even more effective.

Must Read

AstraZeneca commits to supply Europe with 400 million doses of COVID-19 vaccine candidate

AstraZeneca has announced that it has reached an agreement with Europe’s Inclusive Vaccines Alliance (IVA) to supply the continent with up to 400 million...

BioSerenity, Leader in Healthcare as a Service (HaaS), Helps Advance Understanding of COVID-19 Neurological Impact

BioSerenity offers EEG services using remotely connected equipment enabling testing outside of traditional departments.   Hospitals in France requested BioSerenity to perform EEGs in...

Israeli Researchers Say Medical Cannabis Could Effectively Treat Some COVID-19 Symptoms

Israeli researchers from The Medical Cannabis Research and Innovation Center at Haifa’s Rambam Health Care Campus are leading research that suggests the effects of...

COVID-19 second peak could see almost 10 million patients waiting for NHS services, according to new tool

A free online waiting list estimation tool for NHS patients has predicted that almost 10 million people could be waiting for NHS services by...

Redhill Biopharma Expands Opaganib COVID-19 Phase 2/3 Study with Clinical Trial Applications in Italy and UK

Redhill Biopharma Expands Opaganib COVID-19 Phase 2/3 Study with Clinical Trial Applications in Italy and UK Mark L. Levitt, M.D., Ph.D., and Medical Director at...